Overview
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Eligibility
Inclusion Criteria:
- 1.Diagnosed as advanced non-small cell lung cancer
- 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion Criteria:
- The patient is diagnosed with small cell lung cancer